WO2004062569A3 - Cardiolipin compositions their methods of preparation and use - Google Patents

Cardiolipin compositions their methods of preparation and use Download PDF

Info

Publication number
WO2004062569A3
WO2004062569A3 PCT/US2003/013917 US0313917W WO2004062569A3 WO 2004062569 A3 WO2004062569 A3 WO 2004062569A3 US 0313917 W US0313917 W US 0313917W WO 2004062569 A3 WO2004062569 A3 WO 2004062569A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiolipin
liposomes
compositions
preparation
methods
Prior art date
Application number
PCT/US2003/013917
Other languages
French (fr)
Other versions
WO2004062569A2 (en
Inventor
Moghis U Ahmad
Zhen Lin
Shoukath M Ali
Imran Ahmad
Original Assignee
Neopharm Inc
Moghis U Ahmad
Zhen Lin
Shoukath M Ali
Imran Ahmad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc, Moghis U Ahmad, Zhen Lin, Shoukath M Ali, Imran Ahmad filed Critical Neopharm Inc
Priority to AU2003300770A priority Critical patent/AU2003300770A1/en
Priority to PCT/US2003/016412 priority patent/WO2003099830A2/en
Priority to CA002486967A priority patent/CA2486967A1/en
Priority to EA200401565A priority patent/EA200401565A1/en
Priority to JP2004507487A priority patent/JP2006518701A/en
Priority to AU2003239614A priority patent/AU2003239614A1/en
Priority to EP03734162A priority patent/EP1513853A2/en
Priority to JP2005501873A priority patent/JP2006510733A/en
Priority to EP03749443A priority patent/EP1556392A1/en
Priority to CA002502285A priority patent/CA2502285A1/en
Priority to EA200500659A priority patent/EA200500659A1/en
Priority to PCT/US2003/027806 priority patent/WO2004039817A1/en
Priority to AU2003268478A priority patent/AU2003268478A1/en
Priority to CA002501990A priority patent/CA2501990A1/en
Priority to PCT/US2003/033099 priority patent/WO2004035523A1/en
Priority to EA200500661A priority patent/EA200500661A1/en
Priority to JP2005501473A priority patent/JP2006503112A/en
Priority to AU2003277445A priority patent/AU2003277445A1/en
Priority to EP03809159A priority patent/EP1558562A1/en
Publication of WO2004062569A2 publication Critical patent/WO2004062569A2/en
Publication of WO2004062569A3 publication Critical patent/WO2004062569A3/en
Priority to US10/996,536 priority patent/US20050181037A1/en
Priority to HK05112200.6A priority patent/HK1080087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation. The reaction schemes can be used to generate new forms of cardiolipin, including cardiolipin variants. The cardiolipin prepared by the present methods can conveniently be incorporated into liposomes and other lipid formulations that can also include active agents such as hydrophobic or hydrophilic drugs. Such formulations can be used to treat diseases or in diagnostic and/or analytical assays. Liposomes also can include ligands, e.g., for targeting them to a cell type or specific tissue.
PCT/US2003/013917 2002-05-24 2003-05-04 Cardiolipin compositions their methods of preparation and use WO2004062569A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
AU2003300770A AU2003300770A1 (en) 2003-01-07 2003-05-04 Cardiolipin compositions their methods of preparation and use
PCT/US2003/016412 WO2003099830A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
CA002486967A CA2486967A1 (en) 2002-05-24 2003-05-23 Cardiolipin compositions their methods of preparation and use
EA200401565A EA200401565A1 (en) 2002-05-24 2003-05-23 METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
JP2004507487A JP2006518701A (en) 2002-05-24 2003-05-23 Cardiolipin composition, process for its production and use
AU2003239614A AU2003239614A1 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
EP03734162A EP1513853A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
PCT/US2003/027806 WO2004039817A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
EP03749443A EP1556392A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
CA002502285A CA2502285A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
EA200500659A EA200500659A1 (en) 2002-10-16 2003-09-05 Subsidiaries. The process is to get the cardiolipine or its analogue (options) and the contained liposomes.
JP2005501873A JP2006510733A (en) 2002-10-16 2003-09-05 Cardiolipin molecule and synthesis method
AU2003268478A AU2003268478A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
PCT/US2003/033099 WO2004035523A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
CA002501990A CA2501990A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
EA200500661A EA200500661A1 (en) 2002-10-16 2003-10-16 CATION ANALOGUE OF CARDIOLIPINE (OPTIONS), ITS APPLICATION (OPTIONS), COMPOSITION AND SET FOR TRANSFECTION OF CELLS (OPTIONS)
JP2005501473A JP2006503112A (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogues and uses thereof
AU2003277445A AU2003277445A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
EP03809159A EP1558562A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
US10/996,536 US20050181037A1 (en) 2002-05-24 2004-11-23 Cardiolipin compositions their methods of preparation and use
HK05112200.6A HK1080087A1 (en) 2002-10-16 2005-12-30 Cardiolipin molecules and method of synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43865903P 2003-01-07 2003-01-07
US60/438,659 2003-01-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/996,536 Continuation-In-Part US20050181037A1 (en) 2002-05-24 2004-11-23 Cardiolipin compositions their methods of preparation and use

Publications (2)

Publication Number Publication Date
WO2004062569A2 WO2004062569A2 (en) 2004-07-29
WO2004062569A3 true WO2004062569A3 (en) 2004-09-02

Family

ID=32713362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013917 WO2004062569A2 (en) 2002-05-24 2003-05-04 Cardiolipin compositions their methods of preparation and use

Country Status (2)

Country Link
AU (1) AU2003300770A1 (en)
WO (1) WO2004062569A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643260A1 (en) * 2006-02-24 2007-09-07 Neopharm, Inc. Method and process for preparing cardiolipin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5744461A (en) * 1989-11-22 1998-04-28 Nexstar Pharmaceuticals, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US6027726A (en) * 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6306598B1 (en) * 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744461A (en) * 1989-11-22 1998-04-28 Nexstar Pharmaceuticals, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5965519A (en) * 1990-11-01 1999-10-12 Oregon Health Sciences University Covalent polar lipid conjugates with biologically-active compounds for use in salves
US6306598B1 (en) * 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US6027726A (en) * 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORCELLI ET AL: "A Novel glycolipid and phospholipid in the Purple Membrane", BIOCHEMISTRY, vol. 39, 2000, pages 3318 - 3326, XP001164232 *
GUTBERLET ET AL: "Cardiolipin, a-D glucopyranosyl and L-lysylcardiolipin from Gram Positive bacteria", BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1463, 2000, pages 307 - 322, XP004273152 *

Also Published As

Publication number Publication date
WO2004062569A2 (en) 2004-07-29
AU2003300770A8 (en) 2004-08-10
AU2003300770A1 (en) 2004-08-10

Similar Documents

Publication Publication Date Title
WO2003099830A3 (en) Cardiolipin compositions, methods of preparation and use
WO2005120152A3 (en) Cationic lipids and methods of use
EP1764091A3 (en) Improvements in or relating to amphoteric liposomes
DK0478686T3 (en) Flour and phosphorus-containing amphiphilic molecules with surfactant properties
WO2008137758A3 (en) Amino acid lipids and uses thereof
DE60126801D1 (en) LIPID FORMULATIONS FOR TARGETED DELIVERY
DE502006001562D1 (en)
MA34169B1 (en) 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID DERIVATIVES
WO2003013497A1 (en) Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
ATE316333T1 (en) METHOD FOR IN-VIVO DELIVERY OF THERAPEUTIC AGENTS USING LIPOSOMES
WO2001082917A3 (en) Treatment of hypertriglyceridemia and other conditions using lxr modulators
WO2008058156A3 (en) Guggulphospholipid methods and compositions
BRPI0414096A (en) lipid system and methods of use
DE60222573D1 (en) MICROEMULSION-CONTAINING HERBICIDE CONCENTRATES, MICROEMULSIONS AND METHOD
ECSP034883A (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
EA200970238A1 (en) APPLICATION OF OILS WITH DPA (n-6) IN CHILDREN'S FOOD
WO2005079532A3 (en) Methods and compositions for enhancing risc activity in vitro and in vivo
DE69837274D1 (en) METHOD FOR THE SECULATION OF NUCLEIC ACIDS IN LIPID DOUBLE LAYERS
WO2008070463A3 (en) Endoxifen methods and compositions
WO2005030169A8 (en) Methods for preparing oil bodies comprising active ingredients
WO2007111720A8 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2001076644A3 (en) Lipid-based systems for targeting diagnostic agents
WO2008030818A3 (en) Novel liposome compositions
WO2006004935A3 (en) Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
EA200401565A1 (en) METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP